Drug Profile
BIT 314
Alternative Names: BIT-314Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Biotron
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus p7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Hepatitis-C in Australia
- 22 Sep 2017 Preclinical trials in Hepatitis C in Australia (unspecified route) (Biotron pipeline, September 2017)